Meta-analysis of probiotics in children with antibiotic diarrhea finds clear benefits

20 November 2006

A comprehensive meta analysis, recently featured in the Canadian Medical Association Journal, suggests a possible role for probiotics in the prevention of antibiotic-associated diarrhea. Antibiotics disturb the balance of normal microflora in the gut and this disturbance sometimes causes diarrhea, which can often be life-threatening.

The study, which appears in the August issue of the CMAJ, assessed whether probiotics, bacteria that recolonize the gut with non-pathogenic microorganisms, help prevent antibiotic-associated diarrhea in children and concluded that results were "promising."

The findings were welcomed by the maker of Infacol Probiotic Drops, which are the UK's first probiotic oil food supplement specifically designed for children. Infant health food specialist Infacol, the drops help maintain a healthy balance of good bacteria in the digestive system, helping to keep the bad bacteria at bay, which may be the cause of stomach upsets and other gastric problems.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight